Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin

Antiviral Research

Volumn 61, Issue 3, 2004, Pages 195-206

  Xu, Zan ^a   Kuang, Mei ^a   Okicki, James R ^a   Cramer, Hagen ^a   Chaudhary, Nilabh ^a  

^a Ridgeway Biosystems Inc   (United States)

Author keywords

2 5A antisense; Combination therapy; Ribavirin; RNase L; RSV

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; RBI 034; RBI 065; RBI 066; RIBAVIRIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INHIBITION; VIRUS REPLICATION;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 0842332285     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2003.10.005     Document Type: Article

References (36)

1. Banerjee A.K., Barik S., De B.P. Gene expression of nonsegmented negative strand RNA viruses. Pharmacol. Ther. 51(1):1991;47-70.
2. Barnard D.L., Sidwell R.W., Xiao W., Player M.R., Adah S.A., Torrence P.F. 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection. Antiviral Res. 41(3):1999;119-134.
3. Bitko V., Barik S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol. 1(1):2001;34.
4. Cirino N.M., Li G., Xiao W., Torrence P.F., Silverman R.H. Targeting RNA decay with 2′,5′ oligoadenylate-antisense in respiratory syncytial virus-infected cells. Proc. Natl. Acad. Sci. U.S.A. 94(5):1997;1937-1942.
5. Collins P.L., Dickens L.E., Buckler-White A., Olmsted R.A., Spriggs M.K., Camargo E., Coelingh K.V. Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. Proc. Natl. Acad. Sci. U.S.A. 83(13):1986;4594-4598.
6. Collins, P.L., McIntosh, K., Chanock, R.M. (1996). In: Fields, B.N., Knipe, D.M., Howley, P.M. (Eds.), Respiratory Syncytial Virus. Fields Virology, vol. 1. Lippincott-Raven Publishers, Philadelphia, PA, pp. 1313-1351.
7. Cramer H., Player M.R., Torrence P.F. Discrimination between ribonuclease H- and ribonuclease L-mediated RNA degradation by 2′-O-methylated 2-5A-antisense oligonucleotides. Bioorg. Med. Chem. Lett. 9(7):1999;1049-1054.
8. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6(12):2000;1375-1379.
9. Crotty S., Cameron C.E., Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U.S.A. 98(12):2001;6895-6900.
10. Dominguez K.D., Mercier R.C. Treatment of RSV pneumonia in adults - evidence of ribavirin effectiveness? Ann. Pharmacother. 33(6):1999;739-741.
11. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411(6836):2001;494-498.
12. Englund J.A., Piedra P.A., Jefferson L.S., Wilson S.Z., Taber L.H., Gilbert B.E. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J. Pediatr. 117(2 Pt. 1):1990;313-320.
13. Englund J.A., Piedra P.A., Ahn Y.M., Gilbert B.E., Hiatt P. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J. Pediatr. 125(4):1994;635-641.
14. Falsey A.R., Walsh E.E. Respiratory syncytial virus infection in adults. Clin. Microbiol. Rev. 13(3):2000;371-384.
15. Gitlin L., Karelsky S., Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature. 418(6896):2002;430-434.
16. Glezen W.P., Taber L.H., Frank A.L., Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140(6):1986;543-546.
17. Greenough A. Respiratory syncytial virus infection: clinical features, management, and prophylaxis. Curr. Opin. Pulm. Med. 8(3):2002;214-217.
18. Hallander H.O., Dornbusch K., Gezelius L., Jacobson K., Karlsson I. Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method. Antimicrob. Agents Chemother. 22(5):1982;743-752.
19. Hammond S.M., Bernstein E., Beach D., Hannon G.J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature. 404(6775):2000;293-296.
20. Jacque J.M., Triques K., Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature. 418(6896):2002;435-438.
21. Jairath S., Vargas P.B., Hamlin H.A., Field A.K., Kilkuskie R.E. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res. 33(3):1997;201-213.
22. Leaman D.W., Longano F.J., Okicki J.R., Soike K.F., Torrence P.F., Silverman R.H., Cramer H. Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. Virology. 292(1):2002;70-77.
23. Maran A., Maitra R.K., Kumar A., Dong B., Xiao W., Li G., Williams B.R., Torrence P.F., Silverman R.H. Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science. 265(5173):1994;789-792.
24. McIntosh, K., Chanock, R.M. (1990). In: Fields, B., Knipe, D.M., Chanock, R.M., Hirsch. M.S., Melnick, J.L., Monath, T.P., Roizman, B. (Eds.), Respiratory Syncytial Virus. Fileds Virology. Raven Press, New York, pp. 1045-1074.
25. Novina C.D., Murray M.F., Dykxhoorn D.M., Beresford P.J., Riess J., Lee S.K., Collman R.G., Lieberman J., Shankar P., Sharp P.A. siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8(7):2002;681-686.
26. Player M.R., Barnard D.L., Torrence P.F. Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proc. Natl. Acad. Sci. U.S.A. 95(15):1998;8874-8879.
27. Roeckl-Wiedmann I., Liese J.G., Grill E., Fischer B., Carr D., Belohradsky B.G. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur. J. Pediatr. 162(4):2003;237-244.
28. Severson W.E., Schmaljohn C.S., Javadian A., Jonsson C.B. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 77(1):2003;481-488.
29. Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., Anderson L.J. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 282(15):1999;1440-1446.
30. Silverman, R.H. (1997). In: D'Alessio, G., Riordan, J.F. (Eds.), Ribonucleases: Structure and Function. Academic Press, Inc., San Diego, CA, pp. 515-551.
31. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 289(2):2003;179-186.
32. Torrence P.F., Maitra R.K., Lesiak K., Khamnei S., Zhou A., Silverman R.H. Targeting RNA for degradation with a (2′-5′)oligoadenylate- antisense chimera. Proc. Natl. Acad. Sci. U.S.A. 90(4):1993;1300-1304.
33. Torrence P.F., Xiao W., Li G., Cramer H., Player M.R., Silverman R.H. Recruiting the 2-5A system for antisense therapeutics. Antisense Nucleic Acid Drug Dev. 7(3):1997;203-206.
34. Wyde P.R. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res. 39(2):1998;63-79.
35. Zhang L., Peeples M.E., Boucher R.C., Collins P.L., Pickles R.J. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J. Virol. 76(11):2002;5654-5666.
36. Zhou S., Liu R., Baroudy B.M., Malcolm B.A., Reyes G.R. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology. 310(2):2003;333-342.